Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSPO | P30536 | 1/20 | 0.61 |
| ▸ | GRIN1 | Q05586 | 7/20 | 0.46 |
| ▸ | GRIN2B | Q13224 | 7/20 | 0.46 |
| ▸ | MEN1 | O00255 | 1/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.43 |
| ▸ | MAPT | P10636 | 1/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.43 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.43 |
| ▸ | TP53 | P04637 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL7212073 | 0.99 | TSPO (0.60) | TSPOGRIN1GRIN2BMEN1ALDH1A1 | |
| SCHEMBL7217013 | 0.94 | TSPO (0.58) | TSPOGRIN1GRIN2B | |
| SCHEMBL7210705 | 0.93 | TSPO (0.54) | TSPOGRIN1GRIN2B | |
| SCHEMBL7212080 | 0.92 | TSPO (0.55) | TSPOGRIN1GRIN2BALDH1A1MAPT | |
| SCHEMBL7216373 | 0.90 | TSPO (0.55) | TSPOGRIN1GRIN2B | |
| SCHEMBL7215601 | 0.88 | TSPO (0.58) | TSPOGRIN1GRIN2B | |
| SCHEMBL7210493 | 0.86 | TSPO (0.51) | TSPOGRIN1GRIN2BNPSR1 | |
| SCHEMBL6483612 | 0.84 | TSPO (0.85) | TSPOGRIN1GRIN2BALDH1A1TP53 | |
| SCHEMBL7210797 | 0.84 | TSPO (0.57) | TSPOGRIN1GRIN2BALDH1A1 | |
| SCHEMBL7216925 | 0.82 | TSPO (0.56) | TSPOGRIN1GRIN2BALDH1A1MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 18 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6962921-B2 | Dementia remedies containing 2-aryl-8-oxodihydropurine derivatives as the active ingredient | DAINIPPON PHARMACEUTICAL CO., LTD. (JP) | 2005-11-08 | — | — | US | claimed |
| CN-1146566-C | 2-aryl-8-oxodihydropurine derivatives, process for producting same, medicinal conty. same, and intermediates thereof | �ձ���ҩ��ʽ���� | 2004-04-21 | — | — | CN | claimed |
| CN-1466587-A | Dementia therapeutic agent containing 2-aryl-8-oxodihydropurine derivative as active ingredient | �ձ���ҩ��ʽ���� | 2004-01-07 | — | — | CN | claimed |
| US-20030166667-A1 | Dementia remedies containing 2-aryl-8-oxodihydropurine derivatives as the active ingredient | DAINIPPON SUMITOMO PHARMA CO., LTD. (JP) | 2003-09-04 | — | — | US | claimed |
| EP-1036794-B1 | 2-ARYL-8-OXODIHYDROPURINE DERIVATIVES, PROCESS FOR PRODUCING THE SAME, MEDICINAL COMPOSITIONS CONTAINING THE SAME, AND INTERMEDIATES THEREOF | DAINIPPON PHARMACEUTICAL CO (JP) | 2003-08-27 | — | — | EP | claimed |
| EP-1306378-A1 | DEMENTIA REMEDIES CONTAINING 2-ARYL-8-OXODIHYDROPURINE DERIVATIVES AS THE ACTIVE INGREDIENT | Dainippon Pharmaceutical Co., Ltd. (JP) | 2003-05-02 | — | — | EP | claimed |
| US-6372740-B1 | NERVOUS SYSTEM DISORDERS, ANTIEPILEPTIC AGENTS AND ANTIDEPRESSANTS | DAINIPPON PHARMACEUTICAL CO., LTD. (JP) | 2002-04-16 | — | — | US | claimed |
| EP-1036794-A1 | 2-ARYL-8-OXODIHYDROPURINE DERIVATIVES, PROCESS FOR PRODUCING THE SAME, MEDICINAL COMPOSITIONS CONTAINING THE SAME, AND INTERMEDIATES THEREOF | Dainippon Pharmaceutical Co., Ltd. (JP) | 2000-09-20 | — | — | EP | claimed |
| CN-1247578-C | Dementia remedies containing 2-aryl-8-oxodihydropurine derivatives as the active ingredient | DAINIPPON SUMITOMO PHARMACEUTI (JP) | 2006-03-29 | — | — | CN | disclosed |
| US-6962921-B2 | Dementia remedies containing 2-aryl-8-oxodihydropurine derivatives as the active ingredient | DAINIPPON PHARMACEUTICAL CO., LTD. (JP) | 2005-11-08 | — | — | US | disclosed |
| CN-1146566-C | 2-aryl-8-oxodihydropurine derivatives, process for producting same, medicinal conty. same, and intermediates thereof | �ձ���ҩ��ʽ���� | 2004-04-21 | — | — | CN | disclosed |
| CN-1466587-A | Dementia therapeutic agent containing 2-aryl-8-oxodihydropurine derivative as active ingredient | �ձ���ҩ��ʽ���� | 2004-01-07 | — | — | CN | disclosed |
| US-20030166667-A1 | Dementia remedies containing 2-aryl-8-oxodihydropurine derivatives as the active ingredient | DAINIPPON SUMITOMO PHARMA CO., LTD. (JP) | 2003-09-04 | — | — | US | disclosed |
| EP-1036794-B1 | 2-ARYL-8-OXODIHYDROPURINE DERIVATIVES, PROCESS FOR PRODUCING THE SAME, MEDICINAL COMPOSITIONS CONTAINING THE SAME, AND INTERMEDIATES THEREOF | DAINIPPON PHARMACEUTICAL CO (JP) | 2003-08-27 | — | — | EP | disclosed |
| EP-1306378-A1 | DEMENTIA REMEDIES CONTAINING 2-ARYL-8-OXODIHYDROPURINE DERIVATIVES AS THE ACTIVE INGREDIENT | Dainippon Pharmaceutical Co., Ltd. (JP) | 2003-05-02 | — | — | EP | disclosed |
| US-6372740-B1 | NERVOUS SYSTEM DISORDERS, ANTIEPILEPTIC AGENTS AND ANTIDEPRESSANTS | DAINIPPON PHARMACEUTICAL CO., LTD. (JP) | 2002-04-16 | — | — | US | disclosed |
| CN-1284076-A | 2-aryl-8-oxodihydropurine derivatives, process for producting same, medicinal conty. same, and intermediates thereof | DAINIPPON PHARMACEUTICAL CO (JP) | 2001-02-14 | — | — | CN | disclosed |
| EP-1036794-A1 | 2-ARYL-8-OXODIHYDROPURINE DERIVATIVES, PROCESS FOR PRODUCING THE SAME, MEDICINAL COMPOSITIONS CONTAINING THE SAME, AND INTERMEDIATES THEREOF | Dainippon Pharmaceutical Co., Ltd. (JP) | 2000-09-20 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030166667-A1 | Dementia remedies containing 2-aryl-8-oxodihydropurine derivatives as the active ingredient | TDP1, CHRM1, TPMT | TSPO 1016/4885GRIN1 79/4885GRIN2B 430/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.